Date | Title | Description |
05.11.2024 | Navigating the Waters of Biotech and Pharma: A Tale of Leadership and Growth | In the ever-evolving landscape of biotechnology and pharmaceuticals, leadership is the compass guiding companies through turbulent waters. Recent developments at Senhwa Biosciences and Novartis illustrate this dynamic vividly. Each company ... |
05.11.2024 | Navigating Change in Biopharma: Leadership Shifts at Senhwa and Sobi | The biopharmaceutical landscape is a dynamic arena, where leadership changes can signal new directions and strategies. Recently, two companies, Senhwa Biosciences and Swedish Orphan Biovitrum AB (Sobi), have made significant appointments th... |
01.11.2024 | Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director | TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointme... |
29.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised To Increase Healthspan By Manipulating Thymus Functions | Tolerance Bio, a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, announced the closing of its ov... |
20.10.2024 | Tolerance Bio: Pioneering the Future of Immune Health with $17.2 Million Seed Funding | In the world of biopharmaceuticals, innovation is the lifeblood. Tolerance Bio, a Philadelphia-based company, has just secured $17.2 million in seed funding. This financial boost is not just a number; it represents a beacon of hope for many... |
20.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting Function Of The Thymus | Tolerance Bio – a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the closing of its ... |
10.10.2024 | Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform | CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnso... |
25.09.2024 | Synple chem joins US-based eMolecules |
Founded by Benedikt Wanner (Founder & CEO) AND Paula Nichols (Co-founder and CCO) along with their team, Synpl Chem is a pioneering Zurich-based company that specializes in automated chemical synthesis for small molecules drug discover... |
15.09.2024 | New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer | Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive
BARCELONA, Spain, Sept. 15, 2024 /PRNewswire/ ... |
30.08.2024 | Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGF... | Guardant360® CDx is the first blood-based companion diagnostic to be approved in Japan for the detection of EGFR exon 20 insertion mutations
TOKYO, Aug. 30, 2024 /PRNewswire/ -- Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representat... |
29.08.2024 | Biocon Biologics and Mestag Therapeutics: Pioneering Paths in Biosimilars and Cancer Treatment | In the world of biotechnology, innovation is the lifeblood. Two companies, Biocon Biologics and Mestag Therapeutics, are carving their niches in this dynamic landscape. Their recent developments signal a shift in how we approach treatment f... |
29.08.2024 | Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan | BENGALURU, India, Aug. 29, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settleme... |
29.08.2024 | Circio Holding ASA: First half 2024 results | Circio Holding ASA: First half 2024 results
Thu, Aug 29, 2024 07:00 CET Report this content
Oslo, Norway, 29 August 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, today announces... |
28.08.2024 | Mestag Therapeutics Receives £1.5M Grant from Innovate UK’s Cancer Therapeutics Program | Mestag Therapeutics, a Cambridge, MA-based biotech company harnessing new insights into fibroblast-immune interactions, received a £1.5M Grant from Innovate UK’s Cancer Therapeutics Program.
The company intends to use the amount to accelera... |
09.08.2024 | GenScript Biotech Reports First Half 2024 Results | Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development
Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy rev... |
05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
01.08.2024 | The Multiple Myeloma Research Foundation, Road to Victories, begins this August through the California Wine Country | 2024 Road to Victories: California Wine Country August 24-30, 2024
Patients, caregivers, doctors, pharma partners, and supporters will collectively conquer thousands of cycling miles to accelerate a cure.
We are so grateful to these dedicat... |
30.07.2024 | AC Immune receives FDA Fast Track Designation for Alzheimer’s Disease |
AC Immune SA is a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The... |
28.07.2024 | Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder | PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug... |
26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
26.07.2024 | BioVaxys and American Skin Association: Pioneering Paths in Medical Research**
** | ** In the ever-evolving landscape of medical research, two organizations stand out: BioVaxys Technology Corp. and the American Skin Association (ASA). Each is carving a niche in their respective fields, focusing on innovative solutions for ... |
22.07.2024 | AMERICAN SKIN ASSOCIATION ANNOUNCES 2024 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES | NEW YORK, July 22, 2024 /PRNewswire/ -- American Skin Association has announced the names of the three Investigative Scientist Awards. Andrew Ji, MD of Icahn School of Medicine at Mount Sinai was awarded the ASA Sanofi Investigative Scienti... |
10.07.2024 | BOLDEN THERAPEUTICS TO PRESENT AT THE 4TH ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT | PROVIDENCE, R.I., July 10, 2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation... |
08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
01.07.2024 | Janssen Pharma Co., Ltd. Janssen Pharma Co., Ltd. begins using the Johnson & Johnson brand in Japan | - |
01.07.2024 | Janssen Pharma Co., Ltd. Janssen Pharma Co., Ltd. begins using the Johnson & Johnson brand in Japan | Janssen Pharma Co., Ltd.
Janssen Pharma Co., Ltd. begins using the Johnson & Johnson brand in Japan Developing domestic ethical drug business as Johnson & Johnson Innovative Medicine
……
Opening up the future of medicine and deliveri... |
21.06.2024 | Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform | BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully ... |
01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
26.05.2024 | Stress and Skin: A Complex Relationship | Stress can be a silent killer, not just for your mental health but also for your skin. Dermatologists reveal the hidden connection between stress and skin problems, shedding light on how our emotions can manifest physically.
Stress is like ... |
23.05.2024 | McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI | Join us in returning to NYC on June 5th to collaborate with executive leaders in exploring comprehensive methods for auditing AI models regarding bias, performance, and ethical compliance across diverse organizations. Find out how you can a... |
20.05.2024 | Studies Show Linked Biological Pathways Driving Skin Inflammation | NEW YORK, May 20, 2024 /PRNewswire/ -- A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all inf... |
03.05.2024 | Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024 | Company to present, across eight data presentations, new real-world research on the economic value of genetic testing for retinal diseases and the role of automatic deep-learning based algorithms for geographic atrophy
Johnson & Johnson... |
30.04.2024 | Covishield: AZ cites regulators’ view that benefits outweigh risk of ‘extremely rare potential side effects’ | A recent class-action suit in the United Kingdom has put the spotlight on the AstraZeneca-Oxford University combine’s Covid-19 vaccine, and the possible risk of TTS (thrombosis with thrombocytopenia syndrome) linked to this vaccine.
The mul... |
21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
21.03.2024 | FDA Grants Orphan Drug Designation to Cevidoplenib for ITP | PANGYO, South Korea, March 21, 2024 /PRNewswire/ -- Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP).
Oscotec... |
15.03.2024 | Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore | Eris Lifesciences, a chronic therapy-focused drug firm, has acquired the India-branded formulation business of Biocon Biologics, a subsidiary of Biocon, for Rs 1,242 crore. This includes portfolios in insulin, oncology, and critical care.
T... |
14.03.2024 | Addex to Present at the Bio-Europe Spring 2024 Conference | Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio... |
17.10.2023 | B2B SaaS platform for pharmaceutical companies Leucine raises $7M led by Ecolab, others | Leucine, a B2B software-as-a-service (SaaS) startup has raised $7 million in a Series A funding round led by Ecolab Inc., with participation from Pravega Ventures, Axilor Ventures, Techstars, and several angel investors.
Advertisment
The ... |
09.05.2023 | Prevent Blindness Declares Fourth Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 15-21 | Prevent Blindness declares May 15-21, 2023, as the 4th annual “Inherited Retinal Disease (IRD) Genetic Testing Week." “By providing IRD patients with the resources they need to learn more about their diagnosis, as well as how gene ther... |
22.12.2022 | AI Trends For 2023: Industry Experts (And ChatGPT AI) Make Their Predictions | Top 2023 AI Predictionsgetty |
31.05.2022 | Does Your Data & Analytics Strategy Have These 10 Crucial Elements? | 10 critical elements of a winning data strategy roadmap getty |
27.04.2022 | J&J files lawsuit against several pharmacies and distributors over counterfeit HIV medication | Johnson & Johnson is on the attack against distributors and pharmacies that have allegedly sold counterfeit HIV medication being advertised as their product.
The case, which was filed in the Eastern District of New Y... |
25.03.2022 | Janssen Sciences planning further expansion at Ringaskiddy facility | Janssen Sciences has announced an expansion of its biopharmaceutical supply chain facility in Ringaskiddy, Co. Cork, with the potential to create 180 new full-time jobs.
Construction on the expansion has commenced and is expected to take tw... |
16.03.2022 | Jansen Pharma Co., Ltd. Janssen conducts “Health Awareness and Awareness Survey on Cancer / Prostate Cancer” for people in their 50s, and results at the “HALF TiME PROJECT” kick-off event to raise awa... | Janssen Pharma Co., Ltd.
Janssen conducts “Health Awareness and Awareness Survey on Cancer / Prostate Cancer” for people in their 50s and announces the results at the “HALF TiME PROJECT” kick-off event to raise awareness of the correct unde... |
02.03.2022 | Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022 | “AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team... |
14.02.2022 | Johnson & Johnson plans major stroke investment in Galway | Johnson & Johnson (J&J) subsidiary Cerenovus has announced €50m investment over the next three years at its site in Galway.
The project is being supported by taxpayers through state aid from IDA Ireland.
The company said c.30 specia... |
03.12.2021 | Johnson & Johnson : Latest Phase 3 Data for First-in-Class TREMFYA® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintain... | SPRING HOUSE, PENNSYLVANIA, December 3, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheuma... |
23.11.2021 | Johnson & Johnson : European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults | News Release
Media contact:
Kevin Veninga
Mobile: +31 6 1526 8214
Investor contact:
Jennifer McIntyre
Office: +1 (732) 524 3922
European Commission Approves BYANNLI® (6-monthly Paliperidone
Palmitate; PP6M) for the Maintenance Treatment of
... |
18.11.2021 | J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing | J&J and AbbVie are competing for the same Crohn’s disease market with their respective IL-23 drugs, Tremfya and Skyrizi. On Wednesday, J&J’s Janssen unit revealed data it thinks could prove a key differentiator but a... |
01.11.2021 | Janssen Announces Extension of U.S. FDA BLA PDUFA Date for BCMA CAR-T Ciltacabtagene Autoleucel | RARITAN, N.J., November 1, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date to February 28, 2022 fo... |
29.10.2021 | Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV | NEW BRUNSWICK, N.J., October 28, 2021 - Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robus... |
25.10.2021 | Johnson & Johnson : New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn's Disease an... | SPRING HOUSE, PENNSYLVANIA, October 25, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active... |
08.10.2021 | Johnson & Johnson : Award Winner David Julius, Ph.D., Receives a 2021 Nobel Prize | The ability to feel heat or cold is so second-nature to us that we don't often question how we experience these sensations. But it was only relatively recently that researchers discovered the molecular mechanisms that control thermosensatio... |
05.10.2021 | Johnson & Johnson : Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine | NEW BRUNSWICK, N.J., Oct. 5, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson & Johnson C... |
21.09.2021 | Johnson & Johnson : Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. | NEW BRUNSWICK, N.J., Sept. 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection ag... |
19.09.2021 | Johnson & Johnson : RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small ... | New analysis from CHRYSALIS study presented at the ESMO Annual Congress 2021 supports simultaneously targeting the extracellular and catalytic domains of EGFR
September 19, 2021 (RARITAN, N.J.) - The Janssen Pharmaceutical Companies of John... |
01.09.2021 | Johnson & Johnson : Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia | TITUSVILLE, N.J., Sept. 1, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidon... |
25.08.2021 | Scant on details, J&J claims it has data supporting Covid-19 booster shots | Johnson & Johnson is evaluating booster shots in clinical trials that enrolled nearly 2,300 participants, but in announcing data that it said support additional vaccination shot, the company only pointed to a study with results from few... |
19.08.2021 | Philip Morris nabs over 20% of Vectura's shares; Oncopeptides drug may be headed for adcomm, CEO says | About a week after Vectura’s board of directors said they would unanimously back a Philip Morris takeover, the tobacco giant now has control of more than a fifth of the respiratory drugmaker’s shares.
Shareholders with 2... |
19.08.2021 | As Curia expands, it will add API site in upstate New York; In battle against food allergies, Alladapt to build site to prep for PhIII trials | In July, contract manufacturer AMRI rebranded as Curia, and wrangled two biotechs to aid in its move toward global expansion. Thursday. the company announced that it will up its commercial manufacturing at its Rens... |
19.08.2021 | UK's cost-effectiveness gatekeeper wants to provide faster access to more new drugs | The UK’s arbiter of cost-effectiveness decisions for new drugs, known as the National Institute for Health and Care Excellence or NICE, is plotting a major makeover as the gatekeeper has long been famous for rejecting and... |
19.08.2021 | J&J hunts for a Rybrevant label add just months after rare lung cancer approval | J&J won’t be first to market with a treatment for non-small lung cancer patients who have a rare mutation called METex14. But now, the company’s taking a deeper look at some Phase I data in the hopes of positioning its dr... |
19.08.2021 | As Curia expands, it will add API site in upstate New York; In battle against food allergies, Alladapt to build site to prep for PhIII trials | Pennsylvania-based CDMO Recro Pharma is expanding to the West Coast with the acquisition of Irisys, a San Diego CDMO.
The company announced the deal Friday. Recro bought Irisys for about $50 million in cash, shares and a promissory note.
Ir... |
30.07.2021 | UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH) | |
30.07.2021 | UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH) | TITUSVILLE, N.J., July 30, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection for intravenous (IV) ... |
12.07.2021 | Johnson & Johnson : Janssen Announces U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myelo... | News Release
Media Contacts:
Michelle Larkin
Phone: +1 610-304-5842
Satu Glawe
Phone: +49 172-294-6264
Investor Relations:
Jennifer McIntyre
Phone: +1 732-524-3922
U.S. Medical Inquiries:
+1 800-526-7736
Janssen Announces U.S. FDA Approval ... |
23.06.2021 | Janssen Vaccine: What We Know and What We Don't | June 23, 2021 7 min read
This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process. This story originally appeared on The Conversation
By María Milan García , Complutense University of ... |
12.06.2021 | JOHNSON & JOHNSON
Johnson & Johnson : Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients wi... | After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA)... |
12.06.2021 | JOHNSON & JOHNSON
Johnson & Johnson : New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression... | GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress
Raritan, N.J., June 12, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from... |
09.06.2021 | Johnson & Johnson : 5 Ways Johnson & Johnson is Working to Improve the Well-Being of the World by 2025 | Improving the health of people around the world requires a mix of heart, science and ingenuity-something Johnson & Johnson, the largest, most broadly based healthcare company in the world, has known since its founding in 1886. Since 201... |
02.06.2021 | New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumo... | |
02.06.2021 | JOHNSON & JOHNSON
Johnson & Johnson : New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearan... | SPRING HOUSE, PENNSYLVANIA, June 2, 2021 - Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a... |
01.06.2021 | Janssen Pharmaceuticals : Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | News Release
Media Contacts:
Brian Kenney
Phone: +1 215-620-0111
Satu Glawe
Phone: +49 172-294 6264
Investor Relations:
Jennifer McIntyre
Office: +1 732-524-3922
U.S. Medical Inquiries:
+1 800-526-7736
Janssen Announces U.S. FDA Breakthroug... |
26.05.2021 | Janssen Pharmaceuticals : Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life f... | Media Inquiries:
Suzanne Frost
Phone: +1-416-317-0304
Ania DiAntonio
Phone: +1-215-620-9717
Investor Relations:
Christopher DelOrefice
Phone: +1-732-524-2955
Jennifer McIntyre
Phone: +1-732-524-3922
U.S. Medical Inquiries:
+1-800-526-7736
L... |
24.05.2021 | Janssen Pharmaceuticals : Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn's Disease | News Release
Media Contact:
Bridget Kimmel
Mobile: (215) 688-6033
Investor Contacts:
Christopher DelOrefice
Office: (732) 524-2955
Jennifer McIntyre
Office: (732) 524-3922
Janssen Presents Results of First Head-to-Head Study of Biologic The... |
21.05.2021 | JOHNSON & JOHNSON
Johnson & Johnson : RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Inser... | May 21, 2021 (HORSHAM, P.A.) - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatmen... |
23.04.2021 | Johnson & Johnson : New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust... | SPRING HOUSE, PENNSYLVANIA, April 23, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of... |
23.04.2021 | New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improveme... | |
23.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Pso... | SPRING HOUSE, PENNSYLVANIA, April 23, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of... |
22.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine | NEW BRUNSWICK, N.J., April 21, 2021- Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, devel... |
20.04.2021 | Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review | |
20.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review | NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance ... |
20.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) ReviewEMA Confirms Overall Benefit-Risk Profile Remains Positive | NEW BRUNSWICK, N.J., April 20, 2021- Johnson & Johnson (NYSE: JNJ) (the Company) today announcedthat the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the C... |
02.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents | Expansion of ongoing trial to include adolescents 12-17 years of age reflects commitment to people of all ages affected by pandemic
New Brunswick, NJ (April 2, 2021)- Johnson & Johnson (the Company) has begun vaccinating adolescent part... |
31.03.2021 | Janssen Taps Komodo Health to Optimize Site Selection and Patient Recruitment for Clinical Trials | What You Should Know:
– Komodo Health today announced a new client engagement with Janssen solidifying its role as the leading life sciences patient data analytics platform. Janssen Research & Development, LLC (Janssen) will be using Ko... |
26.03.2021 | JOHNSON & JOHNSON
Johnson & Johnson : Janssen Receives Positive CHMP Opinion for PONVORY™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Diseas... | BEERSE, BELGIUM, MARCH 26, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion r... |
19.03.2021 | Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and ... | |
19.03.2021 | A packed MS market is about to get busier as J&J's ponesimod enters the fray | When J&J dropped $30 billion into an Actelion buyout back in 2017, it hoped the biotech’s pipeline would add something fresh to the massive drugmaker’s slow-to-grow portfolio. One of those mid-stage pickups, MS candidate po... |
16.03.2021 | New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years | |
28.02.2021 | Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S. | |
24.02.2021 | Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Month... | |
21.01.2021 | Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV | |
08.12.2020 | FAST Conference Draws 20 Pharmaceutical Companies and Raises Over $2.2 Million for Research on Angelman Syndrome | |
06.11.2020 | TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials | |
06.11.2020 | Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China | Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jenni... |
05.11.2020 | Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual Scientific Program | |
15.10.2020 | New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis | |
30.09.2020 | SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patient... | |